Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 19/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 19/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | DRD4 | P21917 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | FPR3 | P25089 | 1/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.65 |
| ▸ | HTR1B | P28222 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | GPR183 | P32249 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3959643 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EHTR1A | |
| SCHEMBL29623645 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EHTR1A | |
| SCHEMBL524208 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EHTR1A | |
| SCHEMBL29798833 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EHTR1A | |
| Acetic Acid SCHEMBL5450669 | 0.98 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5450250 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EHTR1A | |
| SCHEMBL5447165 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EHTR1A | |
| SCHEMBL5447178 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EHTR1A | |
| SCHEMBL5471417 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EHTR1A | |
| SCHEMBL5450243 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249630-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | claimed |
| US-20050209338-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | US | claimed |
| EP-1478620-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-24 | — | — | EP | claimed |
| WO-2003072539-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-09-04 | — | — | WO | claimed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| CN-110713489-A | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2020-01-21 | — | — | CN | disclosed |
| EP-3119765-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3347353-B1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3119772-B1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3119766-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-20120046284-A1 | Salts and hydrates of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4--cyclohexan-1-yloxy)-7-methoxy-quinazoline, their use as a medicament and the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20070249630-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20050209338-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | US | disclosed |
| EP-1478620-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003072539-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | ADRB2 36/4885ADRB1 23/4885ADRB3 4/4885 |
| US-20050209338-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | ADRB2 89/4885ADRB1 192/4885ADRB3 128/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | ADRB2 1410/4885ADRB1 887/4885ADRB3 1216/4885 |
| US-20120046284-A1 | Salts and hydrates of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4--cyclohexan-1-yloxy)-7-methoxy-quinazoline, their use as a medicament and the preparation thereof | CSNK1D, CSNK1A1, CSNK1A1L | ADRB2 43/4885ADRB1 31/4885ADRB3 84/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | ADRB2 484/4885ADRB1 275/4885ADRB3 276/4885 |
| US-20070249630-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | ADRB2 89/4885ADRB1 192/4885ADRB3 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.